On Wednesday, Citi updated its outlook on Johnson & Johnson (NYSE:JNJ) shares, reducing the price target to $180 from $185 while sustaining a Buy rating for the healthcare giant. The adjustment follows the completion of J&J's acquisition of Shockwave Medical (NASDAQ:SWAV), which was finalized on May 31, 2024. Citi's analysis anticipates that J&J will manage the acquisition in a manner similar to its handling of previous acquisitions such as Abiomed (NASDAQ:ABMD), choosing not to restate historical financials.
The acquisition, valued at approximately $13.1 billion and financed through a combination of cash and debt, is expected to influence J&J's earnings per share (EPS). According to J&J management, the Shockwave Medical acquisition is projected to result in a $0.10 EPS dilution in 2024E, a $0.17 dilution in 2025E, and will become accretive to earnings in 2026.
The financials around the deal have not been fully disclosed, particularly concerning the specifics of the financing mix, expense synergies, and potential revenue synergies. However, management has provided some insights into their expectations regarding the impact of the transaction on the company's financial performance in the coming years.
Citi's continued endorsement of J&J with a Buy rating reflects a positive outlook on the company's strategic investments in high-growth medical technology assets. J&J's portfolio expansion, including companies like Abiomed, Laminar, and now Shockwave Medical, signals a commitment to strengthening its position in the MedTech sector.
In other recent news, Johnson & Johnson has been ordered to pay $260 million in a talc-related lawsuit in Oregon. This development adds to the company's ongoing legal challenges with its talc products. The company is also working on a proposed $6.48 billion settlement to resolve most talc-related lawsuits.
Simultaneously, Johnson & Johnson has completed its acquisition of Shockwave Medical, a move that expands its presence in the medical technology sector, particularly in cardiovascular intervention. This acquisition is expected to accelerate revenue growth for both the company and its MedTech division.
In relation to analyst notes, Goldman Sachs reinstated coverage on Johnson & Johnson with a Neutral rating, citing potential challenges such as loss of exclusivity for key products. Wells Fargo also reiterated an Equal Weight rating on the company following the divestiture of its KVUE shares, a strategic move that resulted in approximately $3.6 billion in acquired funds.
Additionally, US lawmakers have requested a briefing from the FBI regarding GenScript Biotechnology Co and its ties to China. GenScript, a collaborator with Johnson & Johnson in developing the cancer cell therapy Carvykti, has not commented on the committee's request. These are among the recent developments involving Johnson & Johnson.
InvestingPro Insights
Recent analysis from InvestingPro highlights Johnson & Johnson's (NYSE:JNJ) robust financial position and investor-friendly characteristics. With a market capitalization of $351.18 billion and a trailing P/E ratio of 18.26, JNJ presents as a substantial player in the healthcare sector. The company's commitment to shareholder returns is evident through a dividend yield of 3.36% and a remarkable track record of raising its dividend for 54 consecutive years, showcasing its stable cash flow and financial resilience.
InvestingPro Tips suggest that Johnson & Johnson's stock generally trades with low price volatility, which may appeal to investors seeking stability in their portfolio, especially in the context of the recent acquisition of Shockwave Medical. Additionally, the company's operation with a moderate level of debt aligns with Citi's confidence in JNJ's ability to manage its acquisitions effectively. For investors looking for additional insights, there are more InvestingPro Tips available, which can be accessed with a yearly or biyearly Pro and Pro+ subscription using the coupon code PRONEWS24 for an additional 10% off.
Given the company's status as a prominent player in the Pharmaceuticals industry and analysts' predictions of profitability this year, JNJ's strategic investments in the MedTech sector, as noted in Citi's report, are supported by a solid financial foundation. With Johnson & Johnson trading near its 52-week low, investors might consider this an opportune moment to engage with a company that has consistently demonstrated financial strength and a commitment to growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.